Journal of Health Sciences and Medicine

Yazarlar: ["Pınar AKHANLI", "Sema HEPŞEN", "Muhammed KİZİLGUL", "Sevgi BİLEN AYHAN", "Hakan DÜĞER", "Hayri BOSTAN", "Muhammed Erkam SENCAR", "Bekir UCAN", "Erman ÇAKAL"]

Konular:-

DOI:10.32322/jhsm.1202548

Anahtar Kelimeler:SGLT2 inhibitors,Mean platelet volume,Hematocrit

Özet: Aim: We consider mean platelet volume (MPV), a pointer of platelet activity related to type 2 diabetes mellitus (T2DM) and vascular complications, may have a role in patients using Sodium-Glucose Co-Transporter 2 inhibitors (SGLT2i). Therefore, we aimed to evaluate the MPV change after SGLT2i use in diabetic patients. Matherial and Method: Hemogram parameters such as hemoglobin, hematocrit, and MPV in the 0th and 24th weeks of 102 patients with T2DM that received SGLT2i treatment added to their existing medications and of the control group in which participants are compatible in terms of age and gender factor were compared. Results: A significant increase was observed in the values of MPV and hemoglobin in the 0th and 24th weeks (9.3 (8.2-10.3) to 10.1±1.3, p<0.001, 13.9±1.42 to 14.4±1.5 p<0.001, respectively). Similarly, the hematocrit value increased (42±3.7 to 44.2±3.8, p<0.001). There was also a significant increase in both red blood cell (RBC) and platelet counts (5±0.42 to 5.2±0.47, p<0.001, 252,000 (209,000-304,000) to 262,000 (221,000-322,000), p=0.007, respectively). No correlation was identified in patients with T2DM between MPV and age and gender factors, diabetes duration, body mass index (BMI), fasting and postprandial blood glucose, and insulin use. Conclusion: Contrary to the studies analyzing the relation between MPV and T2DM and its complications, we detected that a 24-week SGLT2i treatment led to an increase in MPV value.

---